As early as 2008, researchers proposed that liver steatosis could be prevented by a DDP-4 inhibitor des-fluoro-sitagliptin (DFS) due to a reduction in ER stress in the liver by GLP-1R signaling. The gene discussed is GLP1R; the disease is fatty liver disease.